Tritonpoint Wealth LLC Lowers Stake in Danaher Corporation $DHR

Tritonpoint Wealth LLC cut its position in Danaher Corporation (NYSE:DHR) by 12.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,186 shares of the conglomerate’s stock after selling 8,870 shares during the period. Danaher comprises 1.5% of Tritonpoint Wealth LLC’s portfolio, making the stock its 13th largest holding. Tritonpoint Wealth LLC’s holdings in Danaher were worth $14,943,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPL Wealth Management LLC bought a new stake in Danaher during the third quarter valued at about $25,000. WFA of San Diego LLC bought a new position in shares of Danaher in the second quarter worth about $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Danaher during the third quarter worth about $27,000. Howard Hughes Medical Institute purchased a new stake in shares of Danaher during the second quarter worth about $27,000. Finally, TruNorth Capital Management LLC bought a new stake in Danaher during the 3rd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $191.18 on Friday. The stock has a market capitalization of $135.30 billion, a PE ratio of 37.93, a P/E/G ratio of 2.59 and a beta of 0.95. The business has a 50 day simple moving average of $204.49 and a two-hundred day simple moving average of $214.31. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 27th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.09. The business had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.14 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.8%. This is an increase from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date is Friday, March 27th. Danaher’s dividend payout ratio (DPR) is 31.75%.

Insider Buying and Selling

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on DHR. Guggenheim boosted their price target on Danaher from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Friday, January 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Danaher in a research report on Thursday, January 29th. Argus set a $265.00 target price on shares of Danaher in a report on Wednesday, January 14th. Robert W. Baird set a $251.00 target price on shares of Danaher in a research report on Thursday, January 29th. Finally, Leerink Partners raised their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “outperform” rating in a research note on Friday, January 16th. Nineteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $253.55.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.